Acute Lymphoblastic Leukemia Market Outlook 2031
- The global acute lymphoblastic leukemia market was valued at US$ 2.2 Bn in 2021
- The global market is projected to grow at a CAGR of 7.6% from 2022 to 2031
- The global acute lymphoblastic leukemia market is anticipated to reach more than US$ 4.5 Bn by the end of 2031
Acute Lymphoblastic Leukemia Market Introduction
Acute lymphocytic leukemia (ALL), also called lympholastic leukemia, is a cancer that starts from the early version of white blood cells known as lympholastic in the bone marrow. Overproduction of cancerous lymphoblast is the primary cause of this type of cancer. When a person is suffering from ALL cancer, lymphoblasts are generally overproduced in the bone marrow and constantly multiply, causing damage to the bone marrow by restraining the production of normal cells such as platelets and red blood cells (RBC). These lymphoblasts are also called leukemia cells. As the number of lymphoblast increases in the bone marrow and blood, there is less room for healthy RBCs, white blood cells, and platelets. This could cause anemia, infection, and bleeding. The cancer can also spread to the brain and spinal cord.
Get Sample Copy of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=22886
Increase in Number of Product Approvals to Drive Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market
Rise in number of product approvals for the treatment of acute lymphoblastic leukemia along with robust pipeline product in early and late phases of clinical trials is expected to propel the global acute lymphoblastic leukemia market size during the forecast period. In October 2021, Kite Pharma, Inc., a Gilead Company, announced the U.S. Food and Drug Administration (FDA) approval for Tecartus (brexucabtagene autoleucel) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL cancer). In August 2018, Novartis AG received the European Commission approval for its CAR-T cell therapy (Kymriah) for B-cell acute lymphoblastic leukemia (ALL cancer). In August 2017, Pfizer Inc. received the U.S. FDA approval for BESPONSA (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL cancer).
Rise in Prevalence of Acute Lymphoblastic Leukemia to Propel Global Market
As per global acute lymphoblastic leukemia market trends, surge in number of patients in developing and developed countries is anticipated to increase the demand for therapeutics during the forecast period. According to the National Cancer Institute, an estimated 107,620 people were living with acute lymphocytic leukemia in the U.S. in 2019. According to a recent study, around 412,000 people worldwide are likely to be diagnosed with some type of leukemia, and acute lymphoblastic leukemia accounts for around 12% of all leukemia cases globally. Thus, rise in prevalence of acute lymphoblastic leukemia is a major factor likely to augment the global acute lymphoblastic leukemia market.
Get Report Methodology @ https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=22886
High Incidence Rate and New Product Approvals Fueling B-Cell Acute Lymphoblastic Leukemia Segment
In terms of type, the B-cell acute lymphoblastic leukemia segment accounted for the largest global acute lymphoblastic leukemia market share in 2021, owing to its rapid development rate in early stages and high incidence. According to the National Comprehensive Cancer Network (NCCN), B-cell ALL subtype starts in young cells that develop in the bone marrow and eventually become mature B-cells (B-lymphocytes), leading to a condition known as Burkitt type ALL (mature B-ALL). It is the most commonly occurring subtype of ALL cancer. Rapidly progressing leukemia and new product approvals are anticipated to drive the segment during the forecast period. In 2018, Novartis AG received approval for Kymriah in Japan for the treatment of B-cell acute lymphoblastic leukemia.
Usage in Acute Lymphoblastic Leukemia (ALL) Cancer Treatment Fueling Chemotherapy Segment
Based on treatment, the chemotherapy treatment segment accounted for significant share of the global market in 2021. The segment is projected to grow at a significant CAGR during the forecast period due to the high prescription rate, wide range of products, and easy availability. Chemotherapy (chemo) is the treatment of cancer with drugs. Chemotherapy drugs travel through the bloodstream to cancer cells throughout the body. This makes chemotherapy useful for cancers that have spread throughout the body, such as leukemia. Hence, chemotherapy is one of the key therapeutics used for ALL cancer treatment.
Get Custom Research Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=22886
Advanced Healthcare Infrastructure Bolstering Hospitals Segment
In terms of end-user, the hospitals segment dominated the global market in 2021. The trend is likely to continue during the forecast period. This can be ascribed to the increase in health care infrastructure, favorable reimbursement policies, and surge in awareness about acute lymphoblastic leukemia. Furthermore, hospitals provide advanced medical treatment to treat acute lymphoblastic leukemia patients.
Regional Analysis of Global Acute Lymphoblastic Leukemia Market
As per global acute lymphoblastic leukemia market forecast, North America dominated the global market during the forecast period. The market in the region is driven by the increase in incidence of acute lymphoblastic leukemia, new product approvals, strong product pipeline, and rise in health care expenditure. The acute lymphoblastic leukemia market in Europe is estimated to grow at a CAGR of more than 7.3% during the forecast period. Asia Pacific is expected to be the fastest growing market for acute lymphoblastic leukemia in the next few years. Japan dominated the acute lymphoblastic leukemia market in the region in 2021. The market in India is expected to grow at a high CAGR during the forecast period.
Make an Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=22886
Analysis of Key Players in Global Acute Lymphoblastic Leukemia Market
This report provides profiles of leading players operating in the global acute lymphoblastic leukemia market. These include Sanofi, Pfizer, Novartis AG, F. Hoffmann-La Roche Ltd., Erytech Pharma, Inc., Kite Pharma, Inc., Celgene Corporation, Amgen, Inc., Bristol-Myers Squibb Company, and Spectrum Pharmaceuticals, Inc. Increase in mergers & acquisitions, strategic collaborations, surge in clinical trials, and new product launches are expected to drive the global market during the forecast period. For instance, in January 2017, Novartis AG signed collaborative agreements with various key industry players to co-develop and co-commercialize oncology therapies.
About Us
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update – https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ
Contact
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: [email protected]